Revisions to the Requirements Applicable to Blood, Blood Components and Source Plasma; Correction, 54208 [E7-18799]
Download as PDF
<![CDATA[
54208
Federal Register / Vol. 72, No. 184 / Monday, September 24, 2007 / Rules and Regulations
govern specific domestic licenses to
manufacture or transfer certain items
containing byproduct material and
medical use of byproduct material. In
the direct final rule, NRC stated that if
no significant adverse comments were
received, the direct final rule would
become final on October 29, 2007. The
NRC did not receive any comments that
warranted withdrawal of the direct final
rule. Therefore, this rule will become
effective as scheduled.
Dated at Rockville, Maryland, this 18th day
of September, 2007.
For the Nuclear Regulatory Commission.
Michael T. Lesar,
Chief, Rulemaking, Directives and Editing
Branch, Division of Administrative Services,
Office of Administration.
[FR Doc. E7–18743 Filed 9–21–07; 8:45 am]
BILLING CODE 7590–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Policy (HF–27), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–
7010.
For information regarding the direct
final rule: Stephen M. Ripley,
Center for Biologics Evaluation and
Research (HFM–17), Food and Drug
Administration, 1401 Rockville
Pike, Rockville, MD 20852–1448,
301–827–6210.
SUPPLEMENTARY INFORMATION: In FR Doc.
E7–15943, appearing on page 45883, in
the Federal Register of Thursday,
August 16, 2007, the following
correction is made:
§ 610.53
Oripavine Control
[Corrected]
1. On page 45887, in the amendment
to § 610.53 Dating periods for licensed
biological products, in the table in
paragraph (c), ‘‘65° C’’ is corrected to
read ‘‘-65° C’’ everywhere it appears.
I
Dated: September 17, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–18799 Filed 9–21–07; 8:45 am]
Food and Drug Administration
21 CFR Part 610
BILLING CODE 4160–01–S
[Docket No. 2007N–0264]
Revisions to the Requirements
Applicable to Blood, Blood
Components and Source Plasma;
Correction
AGENCY:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Food and Drug Administration,
Direct final rule; correction.
The Food and Drug
Administration is correcting a direct
final rule that appeared in the Federal
Register of August 16, 2007 (72 FR
45883). That document amended the
biologics regulations by removing,
revising, or updating specific
regulations applicable to blood, blood
components and Source Plasma to be
more consistent with current practices
in the blood industry and to remove
unnecessary or outdated requirements.
A proposal was published as a
companion document to the direct final
rule in the same issue of the Federal
Register (August 16, 2007, 72 FR
45993). Both documents published with
a typographical error in the codified
section. This document corrects the
error in the direct final rule. Elsewhere
in this issue of the Federal Register we
are correcting the error in the proposed
rule.
DATES: This correction is effective
February 19, 2008.
FOR FURTHER INFORMATION CONTACT:
For information regarding this
correction: Joyce Strong, Office of
SUMMARY:
rfrederick on PROD1PC67 with RULES
21 CFR Part 1308
[Docket No. DEA–309F]
HHS.
ACTION:
VerDate Aug<31>2005
12:22 Sep 21, 2007
Jkt 211001
Designation of Oripavine as a Basic
Class of Controlled Substance
Drug Enforcement
Administration (DEA), Justice.
ACTION: Final Rule.
AGENCY:
SUMMARY: This is a final rule issued by
the Drug Enforcement Administration
(DEA) designating oripavine (3-Odemethylthebaine or 6,7,8,14tetradehydro-4,5-alpha-epoxy-6methoxy-17-methylmorphinan-3-ol) as a
basic class in schedule II of the
Controlled Substances Act (CSA).
Although oripavine was not previously
listed in schedule II of the CSA, it has
been controlled in the United States as
a derivative of thebaine and, as such, is
controlled as a schedule II controlled
substance which includes ‘‘Opium and
opiate, and any salt, compound,
derivative, or preparation of opium or
opiate.’’ Oripavine is a derivative of
thebaine, a natural constituent of
opium, hence oripavine has been and
continues to be, by virtue of the
definition of ‘‘narcotic drug’’, a schedule
II controlled substance. International
control of oripavine in schedule I of the
PO 00000
Frm 00002
Fmt 4700
1961 Single Convention on Narcotic
Drugs (1961 Convention) during the
50th session of the Commission on
Narcotic Drugs (CND) in 2007 prompted
the DEA to specifically designate
oripavine as a basic class of controlled
substance in schedule II of the CSA.
DATES: Effective September 24, 2007.
FOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section,
Drug Enforcement Administration,
Washington, DC 20537, by e-mail,
ode@dea.usdoj.gov or by fax, (202) 353–
1263.
SUPPLEMENTARY INFORMATION:
Sfmt 4700
Oripavine (3-O-demethylthebaine or
6,7,8,14-tetradehydro-4,5-alpha-epoxy6-methoxy-17-methylmorphinan-3-ol) is
the international non-proprietary name
for a chemical substance which is
chemically similar to thebaine. It is a
phenanthrene alkaloid contained in
various species of the genus Papaver
and is a major metabolite of thebaine.
Although oripavine was not previously
listed in schedule II of the CSA, it has
been controlled in the United States as
a derivative of thebaine and, as such, is
controlled under 21 U.S.C. 812(c)
Schedule II (a)(1) which includes
‘‘Opium and opiate, and any salt,
compound, derivative, or preparation of
opium or opiate.’’ Oripavine is a
derivative of thebaine, a natural
constituent of opium, hence oripavine
has been and continues to be, by virtue
of the definition of ‘‘narcotic drug’’, a
schedule II controlled substance (21
U.S.C. 802(17)(A); 21 CFR
1308.12(b)(1)(17)). Oripavine is easily
converted into thebaine and thebaine, in
turn, is convertible into morphine and
morphine derivatives. Both thebaine
and morphine are opiates and are
controlled under schedule I of the 1961
Single Convention on Narcotic Drugs
(1961 Convention): Morphine for its
abuse potential and thebaine for its
convertibility into morphine
derivatives.
DEA’s Authority To Control Oripavine
This order is prompted by a letter
dated June 27, 2007, in which the
United States Government was informed
by the Secretary-General of the United
Nations that oripavine has been added
to schedule I of the 1961 Convention.
This letter was prompted by a decision
at the 50th session of the CND in March
2007 to schedule oripavine under
schedule I of the 1961 Convention. As
a signatory Member State to the 1961
Convention, the United States is
obligated to control oripavine under
E:\FR\FM\24SER1.SGM
24SER1
]]>Agencies
[Federal Register Volume 72, Number 184 (Monday, September 24, 2007)]
[Rules and Regulations]
[Page 54208]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-18799]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 610
[Docket No. 2007N-0264]
Revisions to the Requirements Applicable to Blood, Blood
Components and Source Plasma; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Direct final rule; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration is correcting a direct final
rule that appeared in the Federal Register of August 16, 2007 (72 FR
45883). That document amended the biologics regulations by removing,
revising, or updating specific regulations applicable to blood, blood
components and Source Plasma to be more consistent with current
practices in the blood industry and to remove unnecessary or outdated
requirements. A proposal was published as a companion document to the
direct final rule in the same issue of the Federal Register (August 16,
2007, 72 FR 45993). Both documents published with a typographical error
in the codified section. This document corrects the error in the direct
final rule. Elsewhere in this issue of the Federal Register we are
correcting the error in the proposed rule.
DATES: This correction is effective February 19, 2008.
FOR FURTHER INFORMATION CONTACT:
For information regarding this correction: Joyce Strong, Office of
Policy (HF-27), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-7010.
For information regarding the direct final rule: Stephen M. Ripley,
Center for Biologics Evaluation and Research (HFM-17), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-
6210.
SUPPLEMENTARY INFORMATION: In FR Doc. E7-15943, appearing on page
45883, in the Federal Register of Thursday, August 16, 2007, the
following correction is made:
Sec. 610.53 [Corrected]
0
1. On page 45887, in the amendment to Sec. 610.53 Dating periods for
licensed biological products, in the table in paragraph (c), ``65[deg]
C'' is corrected to read ``-65[deg] C'' everywhere it appears.
Dated: September 17, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-18799 Filed 9-21-07; 8:45 am]
BILLING CODE 4160-01-S
